InjectionClinical Overview
Glycopyrrolate Injection (0.2mg/ml) is a synthetic quaternary ammonium antimuscarinic agent on the WHO Model List of Essential Medicines. It competitively blocks muscarinic acetylcholine receptors at peripheral autonomic effector sites without crossing the blood-brain barrier. Indicated for reduction of salivary, tracheobronchial, and pharyngeal secretions preoperatively; intraoperative protection against bradycardia; reversal of neuromuscular blockade (with neostigmine); and acute peptic ulcer spasm adjunctive management.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Administer by intramuscular (IM) or intravenous (IV) injection under clinical monitoring. Adult preanesthetic dose: 0.1 to 0.2 mg IM/IV 30-60 minutes prior to surgery. For neuromuscular reversal: 0.2 mg IV for each 1.0 mg of neostigmine.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Dry mouth (xerostomia), flushing, tachycardia, blurred vision, urinary retention. Rare/Severe: Cardiac arrhythmias, malignant hyperthermia risk in feverish environments, and severe allergic reactions.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in glaucoma, obstructive uropathy, intestinal obstruction, paralytic ileus, toxic megacolon, and unstable cardiovascular status in acute hemorrhage.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or gastrointestinal treatment recommendations. Always consult a registered gastroenterologist or qualified medical practitioner before initiating, altering, or discontinuing any gastrointestinal medication or digestive therapy.
Glycopyrrolate Tablet 1Mg
Glycopyrrolate Tablets (1mg, 2mg) is an oral quaternary ammonium antimuscarinic on the PMBI formulary. It selectively blocks peripheral muscarinic receptors, markedly decreasing basal and stimulated gastric acid secretion and eliminating gastrointestinal smooth muscle spasm without causing central anticholinergic effects (confusion, sedation). Indicated as adjunctive therapy in peptic ulcer disease, severe sialorrhea (drooling), and spastic gastrointestinal disorders.
Glycopyrrolate Tablet 2Mg
Glycopyrrolate Tablets (1mg, 2mg) is an oral quaternary ammonium antimuscarinic on the PMBI formulary. It selectively blocks peripheral muscarinic receptors, markedly decreasing basal and stimulated gastric acid secretion and eliminating gastrointestinal smooth muscle spasm without causing central anticholinergic effects (confusion, sedation). Indicated as adjunctive therapy in peptic ulcer disease, severe sialorrhea (drooling), and spastic gastrointestinal disorders.